Posts tagged Sortina Pharma
Sortina Pharma gör exit från SciLifeLab Drug Discovery and Development Platform
Sortina Pharma gör exit från SciLifeLab Drug Discovery and Development Platform

Sortina Pharma, som fokuserar på utveckling av småmolekylära läkemedel som riktar in sig på målproteinet sortilin, ett nyckelprotein med central roll i cancer och neurodegenerativa sjukdomar – har framgångsrikt avslutat sitt samarbete med SciLifeLabs Drug Discovery and Development Platform (DDD). Projektet har fokuserat på att utforska och vidareutveckla sortilins terapeutiska potential, vilket markerar ett viktigt steg framåt i bolagets ambition att erbjuda innovativa behandlingar för sjukdomar med stora medicinska behov.

Read More
NewsMelisha LinnellSortina Pharma, cancer, cancerbehandling, SciLifeLab, SciLifeLab Drug Discovery and Development Platform, Sara Rhost, Göran Landberg
Lyckat GOKAP Invest möte med delägare och entreprenörer i portföljen
Lyckat GOKAP Invest möte med delägare och entreprenörer i portföljen

Onsdag den 13 mars välkomnades GOKAP Invests stora delägarskara och entreprenörer till ett portföljmöte i Mariasalen vid GU Ventures lokaler i centrala Göteborg. Evenemanget blev välbesökt med drygt 90 investerare på plats.

Read More
NewsMelisha LinnellGOKAP Invest, Investerare, entreprenör, såddinvestering, Klementina Österberg, Sortina Pharma, STD INN AB, Nanolyze AB, Luxbright, Sara Rhost, Signe Svensson, Gaurav Goyal, Mats Alm
Sortina Pharma AB announces official publication of issued Swedish patent
Sortina Pharma AB announces official publication of issued Swedish patent

Sortina Pharma, an oncology focused startup founded in 2020 based on research originating from Gothenburg University, today announces the official publication of the issued Swedish patent no. 2151469-0, which relates to novel sortilin binding molecules inhibiting the binding of effector molecules to sortilin.

Read More
PressreleaseMelisha LinnellSortina Pharma, patent, publication, life science, breast cancer, cancer, cancer treatment
Sortina Pharma AB has appointed Sara Rhost as CEO, with start from 1th of December 2021
Sortina Pharma AB has appointed Sara Rhost as CEO, with start from 1th of December 2021

Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in cancer research and has been one of the lead scientists for the sortilin-project initiated at the University of Gothenburg. She has co-founded Sortina Pharma together with professor Göran Landberg and GU Ventures in 2020.

Read More
PressreleaseMelisha LinnellSortina Pharma, Sara Rhost, GU Ventures, CEO, cancerbehandling, holdingbolaget vid göteborgs universitet
Iscaffpharma and Sortina pharma enter a collaboration agreement to generate cure for cancer
Iscaffpharma and Sortina pharma enter a collaboration agreement to generate cure for cancer

With the agreement that has now been concluded between Iscaffpharma and Sortina Pharma, more effective products to cure aggressive breast cancer can be generated. Sortina Pharma, which is developing a new medical treatment, can now benefit from Iscaffpharma's unique technology. This provides a drug fingerprint predicting the effects in humans for new cancer drugs.

Read More
PressreleaseMelisha LinnellIscaffpharma, Sortina Pharma, agreement